PMID- 33261651
OWN - NLM
STAT- MEDLINE
DCOM- 20210928
LR  - 20210928
IS  - 1477-3155 (Electronic)
IS  - 1477-3155 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Dec 1
TI  - Functionalized silk spheres selectively and effectively deliver a cytotoxic drug 
      to targeted cancer cells in vivo.
PG  - 177
LID - 10.1186/s12951-020-00734-y [doi]
LID - 177
AB  - BACKGROUND: Chemotherapy is often a first-line therapeutic approach for the 
      treatment of a wide variety of cancers. Targeted drug delivery systems (DDSs) can 
      potentially resolve the problem of chemotherapeutic drug off-targeting effects. 
      Herein, we examined in vivo models to determine the efficacy of Her2-targeting 
      silk spheres (H2.1MS1) as DDSs for delivering doxorubicin (Dox) to Her2-positive 
      and Her2-negative primary and metastatic mouse breast cancers. RESULTS: The 
      specific accumulation of H2.1MS1 spheres was demonstrated at the site of 
      Her2-positive cancer. Dox delivered only by functionalized H2.1MS1 particles 
      selectively inhibited Her2-positive cancer growth in primary and metastatic 
      models. Moreover, the significant effect of the Dox dose and the frequency of 
      treatment administration on the therapeutic efficacy was indicated. Although the 
      control MS1 spheres accumulated in the lungs in Her2-positive metastatic breast 
      cancer, the Dox-loaded MS1 particles did not treat cancer. Histopathological 
      examination revealed no systemic toxicity after multiple administrations and at 
      increased doses of Dox-loaded silk spheres. Although the studies were performed 
      in immunocompetent mice, the H2.1MS1 silk spheres efficiently delivered the drug, 
      which exerted a therapeutic effect. CONCLUSION: Our results indicated that 
      functionalized silk spheres that enable cell-specific recognition, cellular 
      internalization, and drug release represent an efficient strategy for cancer 
      treatment in vivo.
FAU - Florczak, Anna
AU  - Florczak A
AD  - Chair of Medical Biotechnology, Poznan University of Medical Sciences, 15 Garbary 
      St, 61-866, Poznan, Poland. annaflorczak@ump.edu.pl.
AD  - Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 
      Garbary St, 61-866, Poznan, Poland. annaflorczak@ump.edu.pl.
FAU - Deptuch, Tomasz
AU  - Deptuch T
AD  - Chair of Medical Biotechnology, Poznan University of Medical Sciences, 15 Garbary 
      St, 61-866, Poznan, Poland.
AD  - Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 
      Garbary St, 61-866, Poznan, Poland.
FAU - Lewandowska, Anna
AU  - Lewandowska A
AD  - Department of Tumor Pathology, Greater Poland Cancer Centre, 15 Garbary St, 
      61-866, Poznan, Poland.
AD  - Department of Tumor Pathology and Prophylaxis, Poznan University of Medical 
      Sciences, 15 Garbary St, 61-866, Poznan, Poland.
FAU - Penderecka, Karolina
AU  - Penderecka K
AD  - Chair of Medical Biotechnology, Poznan University of Medical Sciences, 15 Garbary 
      St, 61-866, Poznan, Poland.
AD  - Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 
      Garbary St, 61-866, Poznan, Poland.
FAU - Kramer, Elzbieta
AU  - Kramer E
AD  - Department of Tumor Pathology, Greater Poland Cancer Centre, 15 Garbary St, 
      61-866, Poznan, Poland.
FAU - Marszalek, Andrzej
AU  - Marszalek A
AD  - Department of Tumor Pathology, Greater Poland Cancer Centre, 15 Garbary St, 
      61-866, Poznan, Poland.
AD  - Department of Tumor Pathology and Prophylaxis, Poznan University of Medical 
      Sciences, 15 Garbary St, 61-866, Poznan, Poland.
FAU - Mackiewicz, Andrzej
AU  - Mackiewicz A
AD  - Chair of Medical Biotechnology, Poznan University of Medical Sciences, 15 Garbary 
      St, 61-866, Poznan, Poland.
AD  - Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 
      Garbary St, 61-866, Poznan, Poland.
FAU - Dams-Kozlowska, Hanna
AU  - Dams-Kozlowska H
AUID- ORCID: 0000-0003-2349-419X
AD  - Chair of Medical Biotechnology, Poznan University of Medical Sciences, 15 Garbary 
      St, 61-866, Poznan, Poland. hanna.dams-kozlowska@wco.pl.
AD  - Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 
      Garbary St, 61-866, Poznan, Poland. hanna.dams-kozlowska@wco.pl.
LA  - eng
GR  - 2014/15/B/NZ7/00903/Narodowe Centrum Nauki/
PT  - Journal Article
DEP - 20201201
PL  - England
TA  - J Nanobiotechnology
JT  - Journal of nanobiotechnology
JID - 101152208
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Silk)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Animals
MH  - *Antineoplastic Agents/chemistry/pharmacokinetics/pharmacology
MH  - Cell Line, Tumor
MH  - *Doxorubicin/chemistry/pharmacokinetics/pharmacology
MH  - Drug Delivery Systems/*methods
MH  - Female
MH  - Humans
MH  - Mammary Neoplasms, Experimental/metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Nanoparticles/*chemistry
MH  - *Silk/chemistry/pharmacokinetics
PMC - PMC7709326
OTO - NOTNLM
OT  - Bioengineering
OT  - Cancer
OT  - Functionalization
OT  - Mouse cancer models
OT  - Particles
OT  - Silk
OT  - Targeted drug delivery
COIS- The authors declare that they have no competing interests.
EDAT- 2020/12/03 06:00
MHDA- 2021/09/29 06:00
PMCR- 2020/12/01
CRDT- 2020/12/02 05:21
PHST- 2020/09/25 00:00 [received]
PHST- 2020/11/19 00:00 [accepted]
PHST- 2020/12/02 05:21 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2021/09/29 06:00 [medline]
PHST- 2020/12/01 00:00 [pmc-release]
AID - 10.1186/s12951-020-00734-y [pii]
AID - 734 [pii]
AID - 10.1186/s12951-020-00734-y [doi]
PST - epublish
SO  - J Nanobiotechnology. 2020 Dec 1;18(1):177. doi: 10.1186/s12951-020-00734-y.